Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Vor Bio logo — Vor Bio's vision is to cure blood cancers through cell and g...

Vor Bio

Vor Bio's vision is to cure blood cancers through cell and genome engineering.

Founded 2016 United States Cambridge, United States 110 employees Post Ipo Equity Total: $267.80M Biotechnology, Health Care +1

General Information

Company Name Vor Bio
Founded Year 2016
Location United States Cambridge, United States +1
Employees 110
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Vor Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Vor Bio

Vor Bio is a biotechnology startup founded in 2016 with a vision to cure blood cancers through cell and genome engineering. The company's slogan, "Vor Bio's vision is to cure blood cancers through cell and genome engineering," encapsulates its ambitious goal. Vor Bio is a clinical-stage company based in the United States that focuses on changing the standard of care for patients with blood cancers. Their approach involves engineering hematopoietic stem cells to enable targeted therapies post-transplant. In December 2022, Vor Bio secured a significant $115.80M in Post-IPO Equity investment from RA Capital Management. This infusion of capital not only demonstrates investor confidence in Vor Bio's mission and technology but also provides the financial resources necessary for the company to advance its clinical programs and continue its research and development efforts. This investment serves as a testament to the potential impact of Vor Bio's innovative approach in tackling blood cancers. Overall, Vor Bio's unique focus on leveraging cell and genome engineering to address blood cancers, combined with the substantial investment it has secured, positions the company as a compelling player in the biotechnology and healthcare industries. Furthermore, the backing of notable investors like RA Capital Management indicates external validation of the company's potential to make a significant mark in the field of oncology.

Taxonomy: biopharma, genome engineering, cell therapy, cancer treatment, immuno-oncology, clinical-stage company, hematopoietic stem cells, targeted therapies, selective targeting, therapy development, immunotherapies, bi-specific antibodies, CAR-T therapy, toxicity management, cancer research

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 1
Investor
07 Dec 2022
Series B •••••• 8
Investor Investor Investor Investor Investor
•••• •••• 		07 Jul 2020
Series A •••••• 1 •••• •••• 14 Feb 2019

Vor Bio Alternatives & Competitors

Vor Bio vs
Metaclipse Therapeutics Corporation
Metaclipse Therapeutics Corporation United States

Delivering breakthrough technologies to treat cancer and infectious disease

Grant
6 employees
Biotechnology, Health and Wellness
Compare Vor Bio vs Metaclipse Therapeutics Corporation
Vor Bio vs
Genelux
Genelux United States

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improvi...

Post Ipo Equity
34 employees
Biopharma, Biotechnology
Compare Vor Bio vs Genelux
Vor Bio vs
iOnctura
iOnctura Switzerland

Developing precision small molecules to combat hard-to-treat tumors.

Series B
28 employees
Biotechnology, Health Care
Compare Vor Bio vs iOnctura

FAQ About Vor Bio

Vor Bio's vision is to cure blood cancers through cell and genome engineering.
Vor Bio was founded in 2016.
Vor Bio is headquartered in Cambridge, United States.
Vor Bio operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Vor Bio has approximately 110 employees.
Vor Bio has completed 3 funding rounds, raising a total of $267.80M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Vor Bio include Metaclipse Therapeutics Corporation, Genelux, iOnctura, Turnstone Biologics, Immuneel Therapeutics Pvt. Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vor Bio and Metaclipse Therapeutics Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Vor Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy